BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 26426994)

  • 21. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
    Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
    Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
    Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
    Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
    Doñate F; Raitano A; Morrison K; An Z; Capo L; Aviña H; Karki S; Morrison K; Yang P; Ou J; Moriya R; Shostak Y; Malik F; Nadell R; Liu W; Satpayev D; Atkinson J; Joseph IB; Pereira DS; Challita-Eid PM; Stover DR
    Clin Cancer Res; 2016 Apr; 22(8):1989-99. PubMed ID: 26589436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
    Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
    Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.
    Schirner M; Hoffmann J; Menrad A; Schneider MR
    Clin Cancer Res; 1998 May; 4(5):1331-6. PubMed ID: 9607594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma.
    Han TD; Shang DH; Tian Y
    Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
    Sinha S; Dwivedi N; Tao S; Jamadar A; Kakade VR; Neil MO; Weiss RH; Enders J; Calvet JP; Thomas SM; Rao R
    Oncogene; 2020 Feb; 39(6):1231-1245. PubMed ID: 31616061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
    Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
    Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor and antiangiogenic activity of Schisandra chinensis polysaccharide in a renal cell carcinoma model.
    Qu HM; Liu SJ; Zhang CY
    Int J Biol Macromol; 2014 May; 66():52-6. PubMed ID: 24556120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of placental growth factor in renal cell carcinoma.
    Bessho H; Wong B; Huang D; Siew EY; Huang D; Tan J; Ong CK; Tan SY; Matsumoto K; Iwamura M; Teh BT
    Anticancer Res; 2015 Jan; 35(1):531-41. PubMed ID: 25550599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apigenin inhibits renal cell carcinoma cell proliferation.
    Meng S; Zhu Y; Li JF; Wang X; Liang Z; Li SQ; Xu X; Chen H; Liu B; Zheng XY; Xie LP
    Oncotarget; 2017 Mar; 8(12):19834-19842. PubMed ID: 28423637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
    Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
    J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.
    Nagaprashantha LD; Vatsyayan R; Singhal J; Lelsani P; Prokai L; Awasthi S; Singhal SS
    Carcinogenesis; 2011 Apr; 32(4):568-75. PubMed ID: 21304051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.